ClinicalTrials.Veeva

Menu

Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain After TKA

U

University Hospital, Gentofte, Copenhagen

Status and phase

Completed
Phase 4

Conditions

Mobility After Total Knee Arthroplasty

Treatments

Drug: Ropivacaine
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01922596
SM3_UG_12
2012-004554-28 (EudraCT Number)

Details and patient eligibility

About

The purpose of the study is to compare the effect of a Adductor Canal Blockade (ACB) vs a Femoral Nerve Blockade (FNB), on muscle strength, mobility and pain in patients with severe pain (VAS pain score > 60) after Total Knee Arthroplasty (TKA.

Full description

The patients will be included after surgery (the first 2 postoperative days). Patients reporting VAS > 60 during active flexion of the knee can be included. All included patients will receive 2 blockades at the same time - an ACB and a FNB, one blockade with 30ml ropivacaine 0,2% and the other with 30ml saline according to randomization.

Prior to, and after, the blockades VAS pain scores will be obtained, muscle strength (quadriceps and adductors) will be measured using a handheld dynanometer and a Timed Up and Go test will be performed.

The study is registered at clinicaltrials.gov after inclusion of the first patient. The reason for this is that we recently became aware of that some journals do not accept a EudraCT registration. The study was registered at EudraCT (2012-004554-28)prior to enrollment of patients.

Enrollment

50 patients

Sex

All

Ages

30 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • TKA within 72 hours and VAS>60 during 45 degrees active flexion of the knee despite conventional pain medication
  • informed consent
  • ASA 1-3
  • BMI 18-40

Exclusion criteria

  • Unable to communicate in Danish
  • Allergic reactions toward ropivacaine
  • Alcohol and or drug abuse
  • Unable to cooperate
  • Known sensory disturbances in the lower limbs

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

50 participants in 2 patient groups

Active FNB, placebo ACB
Experimental group
Description:
FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
Treatment:
Drug: Placebo
Drug: Ropivacaine
Active ACB, placebo FNB
Experimental group
Description:
ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
Treatment:
Drug: Placebo
Drug: Ropivacaine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems